What is included in the long-term monitoring of multiple myeloma (MM)?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Patients with MM may require hospitalization for the treatment of pain or bony pathology.

Patients with MM are at high risk of infection, especially from encapsulated organisms. Vaccinations against pneumococcal organisms and influenza are recommended. Consider vaccinating patients against Haemophilus influenzae type b. Use of the herpes zoster vaccine should be considered.

The following laboratory results are helpful in the follow-up care of patients with MM:

  • Complete blood count (CBC), chemical profile 7 (especially blood urea nitrogen [BUN] and serum creatinine), serum calcium, and serum uric acid, and serum protein electrophoresis (SPEP) findings.
  • M-component level in the serum and/or urine. (This is an indicator of tumor burden; a reduction with chemotherapy is used as a sign of a treatment response.)
  • Serum beta-2 microglobin. (An elevated level indicates a large malignant cell mass, renal impairment, or both.)
  • Serum lactate dehydrogenase (LDH) level. (A high level is predictive of an aggressive lymphomalike course.)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!